Allopurinol
Aloprim
Xanthine Oxidase Inhibitor
NADAC/unit
$0.0331
No Shortage
Tier 1: 177.5%
14 Manufacturers
29 ANDAs
indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adu....
vs. brand Aloprim: Generic saves up to 100% per unit
Active Shortages
2026-02-19 Discontinuation of the manufacture of the drug, Teva Pharmaceuticals USA, Inc.
2026-02-19 Discontinuation of the manufacture of the drug, Teva Pharmaceuticals USA, Inc.
2026-02-19 Discontinuation of the manufacture of the drug, Teva Pharmaceuticals USA, Inc.
2026-02-19 Discontinuation of the manufacture of the drug, Teva Pharmaceuticals USA, Inc.
Market Intelligence
2024-07-10 Class II Recall: Dr. Reddy's Laboratories, Inc.
2024-01-03 Class II Recall: CARDINAL HEALTHCARE
2023-02-01 Class II Recall: Accord Healthcare, Inc.
Generic Manufacturers
ACCORD HEALTHCARE INCAUROBINDO PHARMA LTDCASPER PHARMA LLCCHARTWELL LIFE MOLECULES LLCDR REDDYS LABORATORIES INCGLAND PHARMA LTDHARMAN FINOCHEM LTDHETERO LABS LTD UNIT VHIKMA PHARMACEUTICALS USA INCMYLAN INSTITUTIONAL LLC A VIATRIS COMYLAN PHARMACEUTICALS INCPH HEALTH LTDREGCON HOLDINGS LLCSUN PHARMACEUTICAL INDUSTRIES INCUNICHEM LABORATORIES LTDWATSON LABORATORIES INCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.